Janux Therapeutics, Inc.

Janux Therapeutics Inc. is a biotechnology company focused on developing novel immunotherapies designed to treat a broad range of cancer types. The primary function of the company is to advance its proprietary technology platform called Tumor Activated T Cell Engager (TRACTr) to create targeted cancer therapies. This innovative platform aims to improve the efficacy and safety profile of T cell engagers by limiting systemic exposure and activating T cells only at the tumor site. Janux's approach aims to combat the limitations of current immunotherapies, such as systemic toxicity and limited efficacy. Operating within the biopharmaceutical sector, it plays a critical role in the emerging field of immuno-oncology, seeking to address significant unmet medical needs in cancer treatment. With its headquarters located in La Jolla, California, Janux Therapeutics is positioned to contribute to the evolving landscape of personalized and targeted cancer therapies, highlighting its significance in advancing medical innovations and potentially improving patient outcomes globally.